Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Suspended 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1

Interventions

Nivolumab 3Interviews as Topic 2taxane 1palbociclib 1gedatolisib 1aldesleukin 1X-Rays 1Specimen Handling 1Quality of Life 1Phantoms, Imaging 1Pemetrexed 1Paclitaxel 1Nutritional Status 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Infusions, Parenteral 1Hyperthermic Intraperitoneal Chemotherapy 1E-3810 1Doxorubicin 1Cisplatin 1CTLA-4 Antigen 1Blood Transfusion 1Blood Specimen Collection 1Biopsy 1Behavior Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × gedatolisib × Gynecologic × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡